Lorraine Wonner
Family · Lisbon, OHNPI 1518269661
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,089 and has fallen 98.8% since, to $13 in 2024.
Across 157 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$324
- Astellas Pharma US Inc$223
- Sanofi-aventis U.S. LLC$216
- Bayer$193
- AstraZeneca$178
- Novartis$178
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,55396%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $324 |
| Astellas Pharma US Inc | 9 | $223 |
| Sanofi-aventis U.S. LLC | 15 | $216 |
| Bayer | 9 | $193 |
| AstraZeneca | 13 | $178 |
| Novartis | 10 | $178 |
| GSK | 12 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $122 |
| Pfizer | 7 | $117 |
| Lilly USA, LLC | 7 | $102 |
| Amgen | 5 | $90 |
| Sanofi Pasteur Inc. | 4 | $77 |
| Boehringer Ingelheim | 5 | $76 |
| Johnson & Johnson | 4 | $60 |
| Sunovion Pharmaceuticals Inc. | 4 | $58 |
| Merck | 4 | $54 |
| Novo Nordisk | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Abbott | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Edwards Lifesciences | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Biogen | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,653 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 16 | $255 |
Paid to pharmacies, not to this prescriber.
Other family in Lisbon
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.